Ondansetron - a promising adjunctive treatment for persistent schizophrenia

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND:: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. AIMS:: This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials.gov NCT01121042). METHODS:: The study involved 85 outpatients aged 18-65 years with a diagnosis of schizophrenia or schizoaffective disorder who participated in a two-arm randomized control trial. RESULTS:: Longitudinal analyses revealed adjunctive ondansetron provided significant improvement in the cognitive domain ( p<0.05) as measured by the Positive and Negative Syndrome Scale between baseline and week 12. The analysis of "Combination" showed ondansetron effect on Total Positive and Negative Syndrome Scale, approaching significance by week 12 ( p=0.06). No group differences were obtained in the Montgomery-Asberg Depression Rating Scale or Positive and Negative Syndrome Scale subscales. CONCLUSION:: This treatment trial provides some support for adjunctive ondansetron medication as a treatment for the cognitive disorganization symptoms of schizophrenia.

Original languageEnglish
Pages (from-to)1204-1211
Number of pages8
JournalJournal of Psychopharmacology
Volume32
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • adjunctive treatment
  • ondansetron
  • Schizophrenia
  • serotonin 3 receptor antagonist

Cite this

@article{9b165bca255748cb86315f4b95e3f371,
title = "Ondansetron - a promising adjunctive treatment for persistent schizophrenia",
abstract = "BACKGROUND:: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. AIMS:: This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials.gov NCT01121042). METHODS:: The study involved 85 outpatients aged 18-65 years with a diagnosis of schizophrenia or schizoaffective disorder who participated in a two-arm randomized control trial. RESULTS:: Longitudinal analyses revealed adjunctive ondansetron provided significant improvement in the cognitive domain ( p<0.05) as measured by the Positive and Negative Syndrome Scale between baseline and week 12. The analysis of {"}Combination{"} showed ondansetron effect on Total Positive and Negative Syndrome Scale, approaching significance by week 12 ( p=0.06). No group differences were obtained in the Montgomery-Asberg Depression Rating Scale or Positive and Negative Syndrome Scale subscales. CONCLUSION:: This treatment trial provides some support for adjunctive ondansetron medication as a treatment for the cognitive disorganization symptoms of schizophrenia.",
keywords = "adjunctive treatment, ondansetron, Schizophrenia, serotonin 3 receptor antagonist",
author = "Jayashri Kulkarni and Natalie Thomas and Hudaib, {Abdul Rahman} and Emorfia Gavrilidis and Caroline Gurvich",
year = "2018",
month = "11",
day = "1",
doi = "10.1177/0269881118798608",
language = "English",
volume = "32",
pages = "1204--1211",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "11",

}

Ondansetron - a promising adjunctive treatment for persistent schizophrenia. / Kulkarni, Jayashri; Thomas, Natalie; Hudaib, Abdul Rahman; Gavrilidis, Emorfia; Gurvich, Caroline.

In: Journal of Psychopharmacology, Vol. 32, No. 11, 01.11.2018, p. 1204-1211.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Ondansetron - a promising adjunctive treatment for persistent schizophrenia

AU - Kulkarni, Jayashri

AU - Thomas, Natalie

AU - Hudaib, Abdul Rahman

AU - Gavrilidis, Emorfia

AU - Gurvich, Caroline

PY - 2018/11/1

Y1 - 2018/11/1

N2 - BACKGROUND:: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. AIMS:: This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials.gov NCT01121042). METHODS:: The study involved 85 outpatients aged 18-65 years with a diagnosis of schizophrenia or schizoaffective disorder who participated in a two-arm randomized control trial. RESULTS:: Longitudinal analyses revealed adjunctive ondansetron provided significant improvement in the cognitive domain ( p<0.05) as measured by the Positive and Negative Syndrome Scale between baseline and week 12. The analysis of "Combination" showed ondansetron effect on Total Positive and Negative Syndrome Scale, approaching significance by week 12 ( p=0.06). No group differences were obtained in the Montgomery-Asberg Depression Rating Scale or Positive and Negative Syndrome Scale subscales. CONCLUSION:: This treatment trial provides some support for adjunctive ondansetron medication as a treatment for the cognitive disorganization symptoms of schizophrenia.

AB - BACKGROUND:: Ondansetron is a serotonin 3 receptor antagonist widely used to prevent nausea and vomiting in pregnancy and in patients receiving chemotherapy. There is growing evidence that adjunctive ondansetron treatment improves symptomatology associated with schizophrenia, particularly with respect to the positive, negative and cognitive symptoms. Further studies that are applicable to real world practice are required to assess the efficacy and effectiveness of this treatment, which could be readily and rapidly translated into clinical practice. AIMS:: This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials.gov NCT01121042). METHODS:: The study involved 85 outpatients aged 18-65 years with a diagnosis of schizophrenia or schizoaffective disorder who participated in a two-arm randomized control trial. RESULTS:: Longitudinal analyses revealed adjunctive ondansetron provided significant improvement in the cognitive domain ( p<0.05) as measured by the Positive and Negative Syndrome Scale between baseline and week 12. The analysis of "Combination" showed ondansetron effect on Total Positive and Negative Syndrome Scale, approaching significance by week 12 ( p=0.06). No group differences were obtained in the Montgomery-Asberg Depression Rating Scale or Positive and Negative Syndrome Scale subscales. CONCLUSION:: This treatment trial provides some support for adjunctive ondansetron medication as a treatment for the cognitive disorganization symptoms of schizophrenia.

KW - adjunctive treatment

KW - ondansetron

KW - Schizophrenia

KW - serotonin 3 receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=85056250856&partnerID=8YFLogxK

U2 - 10.1177/0269881118798608

DO - 10.1177/0269881118798608

M3 - Article

VL - 32

SP - 1204

EP - 1211

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 11

ER -